Clik here to view.
BeiGene Presents New Research from Tislelizumab Global Development Program at...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share clinical data and patient-reported outcomes for...
View ArticleClik here to view.
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono...
CAMBRIDGE, Mass. & MONTREAL Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has...
View ArticleClik here to view.
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products...
View ArticleClik here to view.
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
Dr. Reddy’s successfully completes full set of clinical studies of its...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that it...
View ArticleClik here to view.
Genexine Receives Fast Track Designation from Korean Health Authority (MFDS)...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and...
View ArticleClik here to view.
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients...
CORALVILLE, Iowa Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing...
View ArticleClik here to view.
武田薬品がハチメッドのVEGFR1/2/3高選択性の経口チロシンキナーゼ阻害薬フルキンチニブの全世界（中国を除く）を対象とした独占的ライセンス権を取得へ
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — 武田薬品（TSE:4502/NYSE:TAK）は本日、ハチメッド・チャイナ・リミテッド（Nasdaq/AIM: HCM、HKEX: 13）およびその子会社ハチメッド・リミテッドと、中国本土、香港、マカオを除く地域でのフルキンチニブのさらなる開発・商業化に向けて、独占的ライセンス契約を締結したと発表しました。...
View ArticleClik here to view.
KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple...
LEXINGTON, Mass. KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics...
View ArticleClik here to view.
Crown BioscienceがIndivumed GmbHのサービス事業を買収し、バイオバンクをサポートすることに合意
米国 サンディエゴ、ドイツ ハンブルグ （ビジネスワイヤ） — 世界的な医薬品開発業務受託機関（CRO）でJSRライフサイエンス社のCrown Bioscienceは、Indivumed...
View ArticleClik here to view.
冠科生物即将收购Indivumed服务板块及其生物样本库
美国圣地亚哥、德国汉堡 冠科生物——一个全球合同研究组织、JSR生命科学的旗下子公司，宣布其已签订合约收购Indivumed GmbH的IndivuServ业务板块。双方于2022年12月29日敲定了股权购买协议，根据特有结算调整，交易将于2023年四月完成。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank
SAN DIEGO & HAMBURG, Germany Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the...
View ArticleClik here to view.
Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the development of therapies for cancer and autoimmune diseases, announced today that the latest...
View ArticleClik here to view.
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy indicated for the...
View ArticleClik here to view.
武田获得和黄医药的高选择性口服VEGFR1/2/3酪氨酸激酶抑制剂呋喹替尼的全球（中国以外）独家授权
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，与和黄医药（中国）有限公司(Nasdaq/AIM: HCM, HKEX: 13)及其分公司和黄医药有限公司签署独家授权协议，在中国大陆、香港和澳门以外进一步开发和商业化呋喹替尼。...
View ArticleClik here to view.
Qurient Announces Dosing of First Patient in Q702 in Combination with...
SEOUL, South Korea Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient has been dosed in the Phase 1b/2 clinical study of Q702 in...
View ArticleClik here to view.
Shin-Nihon Public Affairs Announces Yasuhisa Shiozaki to join as Special Advisor
TOKYO Shin-Nihon Public Affairs Co. (Head Office: Tokyo; President: Yasushi Kohara) today announced Mr. Yasuhisa Shiozaki as special advisor. Mr. Shiozaki is a former Chief Cabinet Secretary, and...
View ArticleClik here to view.
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two...
View Article